Table 2. Replication of vaccine virus and antibody responses in adults, RSV-seropositive children, and RSV-seronegative children.

ELISA, enzyme-linked immunosorbent assay.

Serum RSV neutralizing
antibody* [mean(SD)]
Serum IgG ELISA RSV F*
[mean (SD)]
SubjectsDose (log10
PFU/ml)
No. of
subjects
%
Infected
% Shedding
virus†
Pre
(SD)
Post
(SD)
≥4-Fold rise
(%)
Pre
(SD)
Post
(SD)
≥4-Fold rise
(%)
Adults
  Vaccinees6.015009.3 (1.1)9.6 (0.9)015.1 (1.2)15.0 (1.2)0
Seropositive children
  Vaccinees6.0101007.5 (1.9)7.7 (1.8)014.2 (2.3)14.0 (2.1)10
  Placebo recipientsPlacebo52008.4 (2.7)9.0 (2.9)2014.8 (1.1)15.6 (1.4)20
Seronegative children
  Vaccinees5.02095852.7 (0.9)6.6 (1.1)957.1 (2.7)13.6 (1.6)90
  Infected placebo
recipient
Placebo11001002.3 (0.0)7.6 (0.0)1005.6 (0.0)13.6 (0.0)100
  Placebo recipientsPlacebo9002.3 (0.0)2.3 (0.0)05.4 (1.5)5.1 (1.0)0

*Antibody data are expressed as reciprocal mean log2 titers.

†% Shedding vaccine virus as detected by culture and/or rRT-qPCR. The limit of detection of vaccine virus was 0.6 log10 PFU/ml.

‡Data from the seronegative placebo recipient, as described in the text.